-
1
-
-
36749039400
-
-
Aloxi [palonosetron hydrochloride package insert, Bloomington, MN: MGI PHARMA, Inc, January 2006
-
Aloxi [palonosetron hydrochloride package insert]. Bloomington, MN: MGI PHARMA, Inc., January 2006.
-
-
-
-
2
-
-
10744219621
-
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
-
Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14(10): 1570-1577.
-
(2003)
Ann Oncol
, vol.14
, Issue.10
, pp. 1570-1577
-
-
Gralla, R.1
Lichinitser, M.2
Van Der Vegt, S.3
-
3
-
-
0344412945
-
Improved prevention of moderate CINV with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial vs dolasetron
-
Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderate CINV with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial vs dolasetron. Cancer 2003; 98(11): 2473-2482.
-
(2003)
Cancer
, vol.98
, Issue.11
, pp. 2473-2482
-
-
Eisenberg, P.1
Figueroa-Vadillo, J.2
Zamora, R.3
-
4
-
-
33748749890
-
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
-
Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17(9): 1441-1449.
-
(2006)
Ann Oncol
, vol.17
, Issue.9
, pp. 1441-1449
-
-
Aapro, M.S.1
Grunberg, S.M.2
Manikhas, G.M.3
-
5
-
-
4644267055
-
Physical and chemical stability of palonosetron HCl in 4 infusion solutions
-
Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann Pharmacother 2004; 38(10): 1608-1611.
-
(2004)
Ann Pharmacother
, vol.38
, Issue.10
, pp. 1608-1611
-
-
Trissel, L.A.1
Xu, Q.A.2
-
6
-
-
13444257970
-
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration
-
Trissel LA, Zhang YP. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration. J Oncol Pharm Pract 2004; 10(4): 191-195.
-
(2004)
J Oncol Pharm Pract
, vol.10
, Issue.4
, pp. 191-195
-
-
Trissel, L.A.1
Zhang, Y.P.2
-
7
-
-
12844288632
-
Palonosetron hydrochloride compatibility and stability with doxorubicin hydrochloride and epirubicin hydrochloride during simulated Y-site administration
-
Trissel LA, Zhang Y. Palonosetron hydrochloride compatibility and stability with doxorubicin hydrochloride and epirubicin hydrochloride during simulated Y-site administration. Ann Pharmacother 2005; 39(2): 280-283.
-
(2005)
Ann Pharmacother
, vol.39
, Issue.2
, pp. 280-283
-
-
Trissel, L.A.1
Zhang, Y.2
-
8
-
-
33847250808
-
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration
-
Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. IJPC 2005; 9(3): 238-241.
-
(2005)
IJPC
, vol.9
, Issue.3
, pp. 238-241
-
-
Trissel, L.A.1
Xu, Q.A.2
-
9
-
-
33847319078
-
Physical and chemical compatibility of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration
-
Trissel LA, Xu QA. Physical and chemical compatibility of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. IJPC 2005; 9(3): 235-237.
-
(2005)
IJPC
, vol.9
, Issue.3
, pp. 235-237
-
-
Trissel, L.A.1
Xu, Q.A.2
-
10
-
-
33847315939
-
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration
-
Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. IJPC 2005; 9(4): 320-322.
-
(2005)
IJPC
, vol.9
, Issue.4
, pp. 320-322
-
-
Trissel, L.A.1
Zhang, Y.2
-
11
-
-
26244449693
-
Physical and chemical stability of palonosetron hydrochloride with cyclophosphamide and ifosfamide during simulated Y-site administration
-
Xu QA, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with cyclophosphamide and ifosfamide during simulated Y-site administration. Am J Health Syst Pharm 2005; 62(19): 1998-2000.
-
(2005)
Am J Health Syst Pharm
, vol.62
, Issue.19
, pp. 1998-2000
-
-
Xu, Q.A.1
Trissel, L.A.2
-
12
-
-
33646479759
-
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and methylprednisolone sodium succinate during simulated Y-site administration
-
Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and methylprednisolone sodium succinate during simulated Y-site administration. IJPC 2006; 10(3): 234-236.
-
(2006)
IJPC
, vol.10
, Issue.3
, pp. 234-236
-
-
Trissel, L.A.1
Zhang, Y.2
Xu, Q.A.3
-
13
-
-
7744220308
-
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration
-
Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health Syst Pharm 2004; 61(15): 1596-1598.
-
(2004)
Am J Health Syst Pharm
, vol.61
, Issue.15
, pp. 1596-1598
-
-
Xu, Q.A.1
Trissel, L.A.2
-
14
-
-
34249824909
-
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration
-
Trissel LA, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. Am J Health Syst Pharm 2007; 64(11): 1209-1213.
-
(2007)
Am J Health Syst Pharm
, vol.64
, Issue.11
, pp. 1209-1213
-
-
Trissel, L.A.1
Trusley, C.2
Ben, M.3
-
15
-
-
36749033975
-
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration
-
In press
-
Ben M, Trusley C, Kupiec TC et al. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. IJPC [In press].
-
IJPC
-
-
Ben, M.1
Trusley, C.2
Kupiec, T.C.3
-
16
-
-
33847272052
-
Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration
-
Trusley C, Ben M, Kupiec TC et al. Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration. IJPC 2007; 11(1): 82-85.
-
(2007)
IJPC
, vol.11
, Issue.1
, pp. 82-85
-
-
Trusley, C.1
Ben, M.2
Kupiec, T.C.3
-
17
-
-
36749014714
-
Palonosetron hydrochloride compatibility and stability with four neuromuscular blocking agents during simulated Y-site administration
-
In press
-
Trusley C, Ben M, Kupiec TC et al. Palonosetron hydrochloride compatibility and stability with four neuromuscular blocking agents during simulated Y-site administration. IJPC [In press].
-
IJPC
-
-
Trusley, C.1
Ben, M.2
Kupiec, T.C.3
-
18
-
-
36749016431
-
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration
-
In press
-
Kupiec TC, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. IJPC [In press].
-
IJPC
-
-
Kupiec, T.C.1
Trusley, C.2
Ben, M.3
-
19
-
-
36749027333
-
Palonosetron hydrochloride compatibility and stability with gentamicin, metronidazole, and vancomycin during simulated Y-site administration
-
In press
-
Kupiec TC, Ben M, Trusley C et al. Palonosetron hydrochloride compatibility and stability with gentamicin, metronidazole, and vancomycin during simulated Y-site administration. IJPC [In press].
-
IJPC
-
-
Kupiec, T.C.1
Ben, M.2
Trusley, C.3
-
20
-
-
0017399410
-
Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets
-
Allen LV Jr, Levinson RS, Phisutsinthrop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm 1977; 34(9): 939-943.
-
(1977)
Am J Hosp Pharm
, vol.34
, Issue.9
, pp. 939-943
-
-
Allen Jr, L.V.1
Levinson, R.S.2
Phisutsinthrop, D.3
-
21
-
-
0026710943
-
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection
-
Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992; 49(7): 1716-1719.
-
(1992)
Am J Hosp Pharm
, vol.49
, Issue.7
, pp. 1716-1719
-
-
Trissel, L.A.1
Bready, B.B.2
-
22
-
-
0027522328
-
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection
-
Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993; 50(2): 300-304.
-
(1993)
Am J Hosp Pharm
, vol.50
, Issue.2
, pp. 300-304
-
-
Trissel, L.A.1
Martinez, J.F.2
-
23
-
-
0027527508
-
Physical compatibility of melphalan with selected drugs during simulated Y-site administration
-
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993; 50(11): 2359-2363.
-
(1993)
Am J Hosp Pharm
, vol.50
, Issue.11
, pp. 2359-2363
-
-
Trissel, L.A.1
Martinez, J.F.2
-
24
-
-
36749098690
-
-
Palonosetron HCl IV Injection 0.05 mg/mL and 0.15 mg/mL end product test procedure. Minneapolis, MN: MGI PHARMA, Inc.; [Undated].
-
Palonosetron HCl IV Injection 0.05 mg/mL and 0.15 mg/mL end product test procedure. Minneapolis, MN: MGI PHARMA, Inc.; [Undated].
-
-
-
|